NCT06346392 2026-03-09
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
AstraZeneca
AstraZeneca
SN BioScience
Onconic Therapeutics Inc.
Jiangsu HengRui Medicine Co., Ltd.
MOMA Therapeutics